Pharmaceutical composition for use in the treatment of periodontal lesions - Patent no. 137477 from 30.06.2025

The invention concerns a biocompatible topical matrix for managing periodontal lesions, comprising hyaluronic acid, melatonin, tetracycline, and metronidazole. The complex was characterized by spectrophotometric techniques (direct and derivative modes), which confirmed preservation of each constituent’s spectral identity and indicated an absence of deleterious intercomponent interactions. These findings support a formulation that enables complementary, potentially synergistic host-modulatory and antimicrobial effects in the biological milieu. For topical use in deep, slowly progressive chronic marginal periodontitis, a paste is proposed with an accurate determined composition.The proposed formulation is a mucoadhesive, topical gel for adjunctive management of periodontal lesions, engineered to couple host-modulation with targeted antimicrobial activity. While, melatonin acts as a pleiotropic immunomodulator and antioxidant—scavenging ROS/RNS, and supporting fibroblast proliferation, angiogenesis, and osteogenic signaling at the lesion site, the hyaluronic acid (medium–high MW) provides a viscoelastic, ECM-mimetic scaffold that retains moisture, promotes granulation and re-epithelialization, and confers substantivity on mucosal surfaces for sustained local delivery. Tetracycline offers broad-spectrum antibacterial action against key periodontal pathogens, while metronidazole complements this with potent activity against obligate anaerobes within the subgingival biofilm. In combination, the actives address the polymicrobial etiology and the dysregulated host response, aiming to reduce pocket inflammation, suppress pathogenic biofilm, and accelerate tissue repair. Aqueous HA gel at near-physiologic pH with light-protected melatonin, stabilized tetracycline, and compatible metronidazole salts can enable controlled release and pocket retention; local administration is intended to minimize systemic exposure. Potential use cases include post–scaling and root planing or peri-implant mucositis management, with outcomes assessed via clinical attachment level, probing depth, bleeding on probing, and microbial load reduction. The first results recorded during clinical trial are promising.